Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of BBOT will decline by -2.54% over the next 2 Weeks and hit $8.79 by Wednesday, July 22, 2026. In that time frame, BBOT's share price is expected to range between $8.45 and $9.16.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper |
|---|---|---|---|
| Jul 22, 2026 | 8.45 | 8.79 | 9.16 |
| Jul 21, 2026 | 8.32 | 8.63 | 9.01 |
| Jul 20, 2026 | 8.64 | 8.99 | 9.33 |
| Jul 17, 2026 | 8.43 | 8.77 | 9.10 |
| Jul 16, 2026 | 8.62 | 8.98 | 9.33 |
| Jul 15, 2026 | 8.43 | 8.76 | 9.08 |
| Jul 14, 2026 | 8.24 | 8.61 | 8.96 |
| Jul 13, 2026 | 8.64 | 8.96 | 9.28 |
| Jul 10, 2026 | 8.40 | 8.74 | 9.11 |
| Jul 9, 2026 | 8.63 | 8.95 | 9.30 |
BBOT shares rose +8.81% in Wednesday, July 8, 2026's trading session, rising from a previous close of $8.29 to move at $9.02. The stock demonstrated notable intraday movement (see BBOT's key stats for a full breakdown), fluctuating between $8.40 and $9.31, a +10.83% trading range. While recent weeks have seen some volatility, BBOT has managed to secure a +21.24% gain over the past 2 weeks. The upward price movement was accompanied by increased trading volume, with approximately 722.53K shares changing hands, 353.16K more than the previous session. This amounted to $6.52M in total market activity.
Will BBOT Continue Its Upward Trend?
According to analyst ratings and projections for BBOT, BridgeBio Oncology Therapeutics Inc. shares are anticipated to increase by +1.48%, potentially reaching $9.16 per share by July 22, 2026. Short-term technical indicators currently suggest a neutral sentiment for BBOT. For deeper insights, view our sentiment analysis on AAPL covering social and institutional perspectives. However, the stock has recorded 13 positive trading days within the past 30 sessions. Based on the BBOT stock forecast, now is a good time to buy BBOT stock because its current trading price is +2.61% above our predicted value, hinting at a possible undervaluation. For deeper insights, view our sentiment analysis on BBOT covering social and institutional perspectives.
BBOT Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into BBOT's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 59.79% to 73.54%) suggest the stock is showing bullish momentum with some volatility. The 50-day RSI, at 50.63%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 48.85%, maintains a neutral outlook for the long term. Insights into BBOT's shareholder base show how institutional investors are positioning themselves during these momentum shifts
BridgeBio Oncology Therapeutics Short-Term Forecasts
BBOT Forecast For Next 5 Days
Our algorithm anticipates BridgeBio Oncology Therapeutics (BBOT) stock could hit $8.48 by Jul 15, 2026. This represents a -6.02% fall from today's price, following a -9.55% change over the past five days.
BBOT Forecast For Next 30 Days
Based on analysis of market trends, the outlook for BridgeBio Oncology Therapeutics Inc. (BBOT) stock over the next 30 days is largely negative. Price forecasts suggest an average target of $8.10, which would mean a -10.20% decrease from the current price of $9.02. Projections for this period range from a high of $9.15 to a low of $7.05.
BBOT Forecast For Next 90 Days
Our proprietary market analysis suggests predictions for BridgeBio Oncology Therapeutics's price over the next three months point to a rise. BBOT stock is expected to peak at $21.11 on Jul 09, 2026 before potentially dipping to $14.02 on Sep 01, 2026. On average, BBOT is likely to trade around $16.64 in the coming 90 days.
BridgeBio Oncology Therapeutics Stock Forecast 2025
Based on our predictive models, BridgeBio Oncology Therapeutics (BBOT) is expected to trade between $13.12 and $21.11 throughout 2026. This would result in an average price of $15.56, potentially offering investors a +72.51% return from current levels.
BridgeBio Oncology Therapeutics Inc. Monthly Forecast 2026–2027
July 2026
According to our latest forecast models, BridgeBio Oncology Therapeutics Inc. (BBOT) is positioned to show a strong performance in July 2026. The price is predicted to move between $16.98 and $21.11, settling at an average of $18.61. This could translate to a +106.32% gain.
August 2026
Based on current market signals, BridgeBio Oncology Therapeutics Inc. is projected to trend august 2026. We forecast a trading range from $14.47 to $18.15, with a likely average price of $16.25. Investors could expect a potential return of +80.16%.
September 2026
Our predictive algorithms indicate BridgeBio Oncology Therapeutics Inc. stock may see a shift in September 2026. The expected range spans $14.02–$17.40, with an average target of $15.96. This represents a positive outlook and a possible gain of +76.94%.
October 2026
Analyzing established trends, BridgeBio Oncology Therapeutics Inc. looks set to move in October 2026. Projections place the stock between $13.51 and $16.00, averaging around $14.89. This suggests a +65.08% gain from current levels.
November 2026
Market indicators suggest BridgeBio Oncology Therapeutics Inc. could experience notable changes during November 2026. Prices could fluctuate within $13.23 to $15.93, with a midpoint forecast of $14.48. The stock might deliver a +60.53% gain.
December 2026
Forecasting for December 2026, models estimate that BridgeBio Oncology Therapeutics Inc. may undergo key fluctuations. If trends hold, the stock might trade between $13.12 and $14.66, averaging $13.89. This signals a positive trajectory with potential returns around +53.99%.
January 2027
According to our latest forecast models, BridgeBio Oncology Therapeutics Inc. (BBOT) is positioned to show a strong performance in January 2027. The price is predicted to move between $10.77 and $13.83, settling at an average of $12.06. This could translate to a +33.70% gain.
February 2027
Based on current market signals, BridgeBio Oncology Therapeutics Inc. is projected to trend february 2027. We forecast a trading range from $8.41 to $11.66, with a likely average price of $10.35. Investors could expect a potential return of +14.75%.
March 2027
Our predictive algorithms indicate BridgeBio Oncology Therapeutics Inc. stock may see a shift in March 2027. The expected range spans $7.05–$9.01, with an average target of $7.84. This represents a cautious outlook and a possible loss of -13.08%.
April 2027
Analyzing established trends, BridgeBio Oncology Therapeutics Inc. looks set to move in April 2027. Projections place the stock between $5.90 and $7.81, averaging around $6.72. This suggests a -25.50% loss from current levels.
May 2027
Market indicators suggest BridgeBio Oncology Therapeutics Inc. could experience notable changes during May 2027. Prices could fluctuate within $5.79 to $6.89, with a midpoint forecast of $6.38. The stock might deliver a -29.27% loss.
June 2027
Forecasting for June 2027, models estimate that BridgeBio Oncology Therapeutics Inc. may undergo key fluctuations. If trends hold, the stock might trade between $4.31 and $6.59, averaging $5.18. This signals a cautious trajectory with potential returns around -42.57%.
July 2027
According to our latest forecast models, BridgeBio Oncology Therapeutics Inc. (BBOT) is positioned to show a strong performance in July 2027. The price is predicted to move between $4.34 and $5.49, settling at an average of $5.00. This could translate to a -44.57% loss.
BBOT's history of dividends and stock splits also plays a role in long-term investor confidence.